Nabriva Therapeutics plc (NBRVF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nabriva Therapeutics plc (NBRVF) trades at $0.0001 with AI Score 57/100 (Grade B). Nabriva Therapeutics plc is a biopharmaceutical company focused on developing novel anti-infective agents for serious infections. Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for NBRVF: NBRVF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NBRVF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
NBRVF: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Nabriva Therapeutics plc (NBRVF) Healthcare & Pipeline Overview
Nabriva Therapeutics plc specializes in the development and commercialization of innovative anti-infective agents, targeting serious bacterial infections with a focus on expanding its product portfolio through advanced clinical trials.
What Is the Investment Thesis for NBRVF?
Nabriva Therapeutics plc presents a unique investment thesis driven by its innovative product pipeline and strategic focus on anti-infective therapies. With SIVEXTRO and XENLETA already on the market, the company is well-positioned to capitalize on the increasing prevalence of antibiotic-resistant infections, a significant global health challenge. The ongoing Phase I clinical trials for XENLETA and CONTEPO may unlock substantial revenue opportunities, particularly in pediatric and complicated urinary tract infection markets, which are projected to grow significantly. Furthermore, the company's negative profit margin of -160.3% highlights the potential for operational improvements as it scales its commercial activities. Investors should monitor Nabriva's progress in clinical trials and regulatory approvals, as successful outcomes could lead to substantial market penetration and revenue growth.
Based on FMP financials and quantitative analysis
NBRVF Key Highlights
- Market Cap: $0.00B, reflecting the early-stage nature of the company.
- Profit Margin: -160.3%, indicating significant investment in R&D with potential for future profitability.
- Gross Margin: 19.9%, highlighting the cost structure associated with product sales.
- Beta: -0.68, suggesting lower volatility compared to the market.
- No dividend yield, consistent with a growth-focused biopharmaceutical company.
Who Are NBRVF's Competitors?
NBRVF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRK Merck & Co., Inc. | $124.41 | -2.42% | $307B | 85 |
| PFE Pfizer Inc. | $24.86 | +0.44% | $142B | 66 |
| GILD Gilead Sciences, Inc. | $129.78 | -2.57% | $161B | 94 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | -9.09% | $7.95M | 72 |
| BLRX BioLineRx Ltd. | $2.92 | +3.18% | $12.7M | 69 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.02 | -1.95% | $165M | 76 |
| CGEN Compugen Ltd. | $2.49 | +6.41% | $235M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NBRVF's Key Strengths?
- Innovative product offerings with potential to address serious infections.
- Experienced leadership team with a strong background in biopharmaceuticals.
- Established products with market presence, such as SIVEXTRO.
What Are NBRVF's Weaknesses?
- Negative profit margin indicating significant operational costs.
- Limited workforce may constrain growth and operational capacity.
- Dependence on successful clinical trials for future revenue generation.
What Could Drive NBRVF Stock Higher?
- Results from ongoing Phase I clinical trials for XENLETA and CONTEPO, which could lead to new product approvals.
- Commercial sales of SIVEXTRO and XENLETA, contributing to revenue generation.
- Potential partnerships with larger pharmaceutical companies to enhance research capabilities.
What Are the Key Risks for NBRVF?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory delays in obtaining approvals for new products could impact timelines.
- Intense competition from established pharmaceutical companies may affect market share.
- Dependence on successful clinical trials for future revenue generation poses risks.
What Are the Growth Opportunities for NBRVF?
- Expansion of XENLETA: Nabriva is advancing XENLETA for multiple indications, including pediatric infections and cystic fibrosis. The pediatric antibiotic market is expected to grow at a CAGR of 5.2%, driven by increasing awareness and diagnosis rates. Successful trials could lead to significant market entry by 2027.
- Development of CONTEPO: Targeting complicated urinary tract infections, CONTEPO is positioned in a market projected to reach $7.6 billion by 2025. The ongoing Phase I trials could pave the way for regulatory approval and market launch, potentially generating substantial revenue.
- Increasing Prevalence of Antibiotic Resistance: The global rise in antibiotic-resistant infections creates a pressing need for new treatments. Nabriva's innovative products, like SIVEXTRO and XENLETA, align with this trend, positioning the company to capture market share as healthcare providers seek effective solutions.
- Strategic Partnerships: Collaborations with larger pharmaceutical companies could enhance Nabriva's research capabilities and accelerate product development. Such partnerships may also provide financial support and facilitate access to broader distribution networks.
- Geographic Expansion: Nabriva has opportunities to expand its market presence beyond its current focus areas. By entering emerging markets where antibiotic resistance is a growing concern, the company could enhance its revenue potential and brand recognition.
What Opportunities Does NBRVF Have?
- Growing demand for effective anti-infective therapies due to rising antibiotic resistance.
- Potential for geographic expansion into emerging markets.
- Partnerships with larger pharmaceutical companies to enhance R&D capabilities.
What Threats Does NBRVF Face?
- Intense competition from established pharmaceutical companies.
- Regulatory hurdles that could delay product approvals.
- Market volatility affecting funding and investment opportunities.
What Are NBRVF's Competitive Advantages?
- Innovative product pipeline targeting unmet medical needs.
- Strong focus on research and development in anti-infective therapies.
- Regulatory expertise in navigating approval processes for new drugs.
What Does NBRVF Do?
Nabriva Therapeutics plc, founded in 2005 and headquartered in Dublin, Ireland, is a biopharmaceutical company dedicated to developing and commercializing novel anti-infective agents to address serious infections. Initially established as Nabriva Therapeutics Forschungs GmbH, the company rebranded in 2007 to reflect its global ambitions. Nabriva's flagship products include SIVEXTRO, an oxazolidinone-class antibacterial approved for treating acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic available for both oral and intravenous administration. The company is actively pursuing the development of XENLETA for several indications, including pediatric infections, sexually transmitted infections, cystic fibrosis, and various types of pneumonia and infections related to surgical procedures. Additionally, Nabriva is advancing CONTEPO, an epoxide antibiotic targeting complicated urinary tract infections, currently in Phase I clinical trials for peri-operative prophylaxis. With a lean workforce of 39 employees, Nabriva is positioned to leverage its innovative research and development capabilities to meet the growing demand for effective anti-infective therapies worldwide.
What Products and Services Does NBRVF Offer?
- Develops novel anti-infective agents to treat serious infections.
- Commercializes SIVEXTRO, an antibacterial for ABSSSI.
- Offers XENLETA, a semi-synthetic antibiotic for oral and IV use.
- Conducts clinical trials to expand treatment indications for existing products.
- Researches new antibiotics to combat antibiotic resistance.
- Focuses on regulatory approvals for its product pipeline.
How Does NBRVF Make Money?
- Generates revenue through the sale of approved pharmaceuticals.
- Engages in partnerships for research and development funding.
- Pursues grants and funding for clinical trials and product development.
- Explores licensing agreements for product distribution and marketing.
What Industry Does NBRVF Operate In?
The biotechnology industry is experiencing rapid growth, driven by advancements in drug development and increasing demand for novel therapies to combat antibiotic resistance. The global anti-infective market is projected to expand significantly, with a focus on innovative solutions that address unmet medical needs. Nabriva Therapeutics operates within this dynamic landscape, competing with established pharmaceutical companies and emerging biotech firms. The company's focus on anti-infective agents positions it well to capture market share as healthcare providers seek effective treatments for resistant infections.
Who Are NBRVF's Key Customers?
- Healthcare providers and hospitals requiring effective anti-infective treatments.
- Pharmaceutical distributors and wholesalers.
- Patients suffering from serious bacterial infections.
Company Profile
Nabriva Therapeutics plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Dublin, IE. The company is led by CEO H. Michael Hogan. NBRVF has traded publicly since 2023.
Nabriva Therapeutics plc (NBRVF) Valuation Context
Relative to its peer group, NBRVF's quantitative score of 57/100 is below the peer average of 77/100.
F-Score 3/9Financial Health
Nabriva Therapeutics plc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
FY2026 estForward Outlook
Wall Street analysts project Nabriva Therapeutics plc revenue of about $163.8M for fiscal 2026, with EPS near $8.91.
NBRVF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see value, signaling potential upside.
- Community sentiment indicates growing belief in the company's pipeline, especially its antibiotic offerings.
- Positive buzz around potential partnerships could lead to increased market confidence and future revenue streams.
- The company's focus on addressing unmet needs in the antibiotic space positions it well against growing antibiotic resistance.
Bear Case
- Limited market traction for existing products raises concerns about revenue generation.
- Negative community chatter highlights worries about the company's cash runway and potential need for dilution.
- Increased competition in the antibiotic market could squeeze margins and limit market share.
- Recent market developments suggest a shift away from smaller biotech firms, impacting investor sentiment towards NBRVF.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
NBRVF Latest News
No recent news available for NBRVF.
NBRVF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NBRVF.
Price Targets
Wall Street price target analysis for NBRVF.
NBRVF MoonshotScore
What does this score mean?
The MoonshotScore rates NBRVF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: H. Michael Hogan
CEO
H. Michael Hogan has extensive experience in the biopharmaceutical industry, having held various leadership roles in both public and private companies. He has a strong background in strategic planning and operational management, with a focus on driving growth and innovation. Hogan has successfully led teams in developing and commercializing pharmaceutical products, contributing to significant advancements in the field.
Track Record: Under Hogan's leadership, Nabriva has made substantial progress in advancing its clinical trials and expanding its product pipeline. His strategic vision has positioned the company to address critical healthcare needs, particularly in the anti-infective space.
NBRVF OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for higher tiers such as OTCQX or OTCQB. These companies may have less stringent reporting requirements, leading to lower visibility in the market compared to those listed on major exchanges like NYSE or NASDAQ.
- OTC Tier: OTC Other
- Lower liquidity compared to stocks listed on major exchanges, potentially impacting trading.
- Lack of stringent reporting requirements may result in less transparency.
- Increased volatility due to lower trading volumes and investor interest.
- Verify the company's financial health and operational metrics.
- Assess the progress of clinical trials and regulatory approvals.
- Review the management team's experience and track record.
- Examine market trends and competitive landscape.
- Investigate any legal or regulatory issues affecting the company.
- Established product offerings with market presence.
- Experienced leadership team with a strong background in pharmaceuticals.
- Ongoing clinical trials indicating commitment to innovation.
NBRVF Healthcare Stock FAQ
What does the AI Score mean for NBRVF?
NBRVF holds an AI Score of 57/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Nabriva Therapeutics plc is a biopharmaceutical company focused on developing novel anti-infective agents for serious infections. Its key products include SIVEXTRO and XENLETA, with ongoing …
What does Nabriva Therapeutics plc do?
Nabriva Therapeutics plc is a biopharmaceutical company focused on developing and commercializing innovative anti-infective agents. The company specializes in treatments for serious infections, with key products including SIVEXTRO and XENLETA, and is actively pursuing additional indications through ongoing clinical trials.
What are the main risks for NBRVF?
Nabriva Therapeutics faces several risks, including regulatory delays that could hinder product approvals, intense competition from larger pharmaceutical companies, and a reliance on successful clinical trials for future revenue. These factors could significantly impact the company's growth trajectory and market position.
How does Nabriva Therapeutics plc navigate regulatory approval processes?
Nabriva Therapeutics employs a strategic approach to navigate regulatory approval processes, focusing on compliance with FDA and EMA guidelines. The company has a track record of successfully bringing products to market, leveraging its expertise in clinical trial design and regulatory submissions to facilitate timely approvals.
What are the key factors to evaluate for NBRVF?
Nabriva Therapeutics plc (NBRVF) holds an AI score of 57/100 (moderate). Not financial advice.
How frequently does NBRVF data refresh on this page?
NBRVF's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NBRVF's recent stock price performance?
Nabriva Therapeutics plc (NBRVF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offerings with potential to address serious infections. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NBRVF overvalued or undervalued right now?
Nabriva Therapeutics plc (NBRVF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NBRVF before investing?
Before investing in Nabriva Therapeutics plc (NBRVF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the latest available reports; ongoing developments may impact metrics.